





an Open Access Journal by MDPI

Advances in Nanoparticle-Based Drug Delivery Systems for Tumor-Targeted Combination Treatment

Guest Editors:

Prof. Dr. Zifu Li

Dr. Xiao Dong

Department of Pharmacy, School of Medicine, Shanghai University, Shanghai 200444, China

Deadline for manuscript submissions:

31 August 2024

Message from the Guest Editors

Dear Colleagues,

In this Special Issue, we will focus on recent advances in tumor-targeted combination therapy strategies based on the design of nano-drug delivery systems. The complexity and heterogeneity of tumors result in critical obstacles that severely impede treatment efficiency. Therefore, it is impossible to eliminate drug-resistant tumors and prevent cancer metastasis using a single treatment modality. Nanomedicine-mediated combination therapies provide promising approaches to synergistically potentiating the therapeutic efficacy of treatments against malignancies or to exerting superadditive (namely "1 + 1 > 2") effects that are stronger than those of any monotherapy or their theoretical combinations.

This Special Issue aims to publish high-quality research papers and reviews focusing on the design, synthesis, and applications of nanomedicines for tumor multimodal synergistic therapy. Both original research articles and reviews are welcome.

We look forward to receiving your contributions.

Prof. Dr. Zifu Li Dr. Xiao Dong Guest Editors







IMPACT FACTOR 4.9





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us